JVRS 100

Drug Profile

JVRS 100

Alternative Names: JVRS-100

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Juvaris BioTherapeutics
  • Developer Penn State Milton S. Hershey Medical Center
  • Class Adjuvants; Antineoplastics; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Leukaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Leukaemia in USA (IV, Infusion)
  • 10 Sep 2011 JVRS 100 licensed to Colby Pharmaceutical Company worldwide
  • 05 Oct 2010 Pharmacodynamics data from preclinical trials released by Juvaris
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top